Cardiotoxicity of different 5-HT3 receptor antagonists analyzed using the FAERS database and pharmacokinetic study

To comprehensively compare the risk of cardiotoxicity with 5-HT3 receptor antagonists (5-HT3RAs) and to explore the underlying pharmacokinetic factors that might contribute to cardiotoxicity. The FDA Adverse Event Reporting System (FAERS) data (January 2004 to March 2023) were extracted. Disproportionality analysis, sensitivity analyses, and time-to-onset assessments were conducted to evaluate cardiac risk signals associated with 5-HT3RAs. Physiologically based pharmacokinetic (PBPK) models were...